Keros Therapeutics
KROS
147 hedge funds and large institutions have $2.08B invested in Keros Therapeutics in 2024 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 57 increasing their positions, 40 reducing their positions, and 10 closing their positions.
270% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 10
96% more capital invested
Capital invested by funds: $1.06B → $2.08B (+$1.02B)
68% more call options, than puts
Call options by funds: $4.81M | Put options by funds: $2.86M
43% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 40
21% more funds holding
Funds holding: 121 → 147 (+26)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1.78% less ownership
Funds ownership: 89.03% → 87.25% (-1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$67.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$52.8M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$52.1M |
| 4 |
Holocene Advisors
New York
|
+$37.8M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$36.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$92.6M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$22.6M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$20.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$18.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.9M |
KROS Hedge Fund Activity: Q1 2024 in Review
147 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2024, worth a combined $2.08B — up 96% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new KROS positions and 10 closed out — a net gain of 27 holders — while 57 added to existing stakes and 40 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $67.9M. The largest seller was Morgan Stanley, cutting an estimated $92.6M.
- 147 institutional investors held Keros Therapeutics (KROS) as of Q1 2024, up from 121 in Q4 2023.
- Funds reported $2.08B of Keros Therapeutics stock for Q1 2024, up 96% quarter-over-quarter.
- 37 funds opened new Keros Therapeutics positions in Q1 2024 and 10 closed out, a net change of +27 holders.
- The largest Keros Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $67.9M added.
- The largest Keros Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $92.6M sold.
Based on aggregated 13F filings for Q1 2024.